18 and older, any sex, with Parkinson Disease or Cognitive Impairment, Mild. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Mild Cognitive ImpairmentPrimary· baseline
Mild cognitive impairment classified by Movement Disorders Society Task Force Level II Critieria
Parkinson's disease with mild Cognitive Impairment
Group
Value
95% CI
Parkinson's Disease
25
Control
0
Parkinson's disease with normal cognition
Group
Value
95% CI
Parkinson's Disease
23
Control
9
Mean Fundamental FrequencyPrimary· baseline
These acoustic measures during spontaneous speech (picture description) were calculated using Praat
Group
Value
95% CI
Parkinson's Disease
137.7
± 39.6
Parkinson's Disease With Mild Cognitive Impairment
142.4
± 39.6
Controls
166.4
± 29.7
Sponsor's own description
The Investigators aim to identify speech and language markers that provide information on cognitive function and predict cognitive decline in Parkinson's disease. The Investigators will administer speech tasks and cognitive assessments to participants with Parkinson's disease and healthy controls. The Investigators will also explore the associations between genetic factors and speech and cognitive status in Parkinson's disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT07399496 — Accelerated TMS for Apathy in PD
· NA
· recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients
· Phase 1
· recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients
· NA
· recruiting
NCT06848205 — Percept Transitions in FOG and PD
· NA
· recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P
· Phase 2
· recruiting
Other University of Massachusetts, Worcester trials
Trials by the same sponsor.
NCT07431528 — Dementia and Storytelling in Vietnam
· NA
· not yet recruiting
NCT07060664 — Study on Outcomes of Proximal Humerus Fractures
· NA
· not yet recruiting
NCT07520110 — Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis
· Phase 3
· not yet recruiting
NCT06100809 — Does Fatigue Coaching Improve Functioning and Fatigue in Resident Night Shifts
· NA
· not yet recruiting
NCT06246539 — Impact of a Virtual Reality-based Mindfulness Program on Clinician Wellness
· NA
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Massachusetts, Worcester
Last refreshed: 10 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04273672.